SEC Tracker
Get the app

Atara Biotherapeutics ATRA

Atara Biotherapeutics reports Q3 2026 results

Atara Biotherapeutics (ATRA) filed an 8-K with the SEC on Nov 10, 2026, 4:11 pm ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Cash, cash equivalents, and short-term investments: $9.9 million as of Sept 30, 2026
  2. Net loss of $2.2 million for Q3 2026, or ($0.15) per share
  3. Operating expenses down 83% year-over-year
  4. Cash runway expected to fund operations into mid-2027

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Atara Biotherapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.